# A Study to Assess the Bioequivalence of Aprepitant and Fosaprepitant and the Effect of Food on Aprepitant Bioavailability (0869-165)

> **NCT00945321** · PHASE1 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 42 (actual)

## Conditions studied

- Chemotherapy-Induced Nausea and Vomiting

## Interventions

- **DRUG:** aprepitant 165 mg
- **DRUG:** Comparator: aprepitant 185 mg
- **DRUG:** Comparator: fosaprepitant 150 mg
- **DRUG:** Comparator: aprepitant with food

## Key facts

- **NCT ID:** NCT00945321
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-02
- **Primary completion:** 2009-03
- **Final completion:** 2009-03
- **Target enrollment:** 42 (ACTUAL)
- **Last updated:** 2015-01-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00945321

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00945321, "A Study to Assess the Bioequivalence of Aprepitant and Fosaprepitant and the Effect of Food on Aprepitant Bioavailability (0869-165)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00945321. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*